Dernières nouvelles pour bluebird bio (NASDAQ:BLUE) Stock

bluebird bio

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

bluebird bio Inc

BLUE HOLDINGS INC by Blue Holdings, Inc.

BLUE WORLD ACQUISITION CORP USD RTS

BLUERIVER ACQUISITION CORP CL A ORD SHS

BLUESCAPE OPPORTUNITIES ACQUISITION CORP CL A

Blue Apron Holdings Inc COM PAR $

Blue Biofuels Inc

Blue Bird Corp

Blue Capital Reinsurance Holdings Ltd

BLUE DIAMOND VENTURES INC by Blue Diamond Ventures, Inc.

Blue Diamond Ventures Inc

BLUE DOLPHIN ENERGY CO by Blue Dolphin Energy Co.

Blue Dolphin Energy Co

BLUE EARTH RES INC by Blue Earth Resources, Inc.

Blue Earth Resources Inc

Blue Energy Ltd

Blue Foundry Bancorp

BLUE GEM ENTERPRISE by Blue Gem Enterprise

Blue Gem Enterprise

Blue Hat Interactive Entertainment Technology - Ordinary Shares

Blue Hat Interactive Entertainment Technology

CANOPUS BIOPHARMA INC by Canopus Biopharma, Inc.

Blue Heaven Coffee Inc

BLUE HORIZON GLOBAL CAP by BLUE HORIZON GLOBAL CAP CORP.

Blue Horizon Global Capital Corp

BLUE LAGOON RESOURCES INC by Blue Lagoon Resources Inc.

Blue Lagoon Resources Inc

BLUE LINE PROTECTION GRP by Blue Line Protection Group, Inc.

Blue Line Protection Group Inc

BLUE MOON GRP UNSP/ADR by Blue Moon Group Holdings Limited

Blue Moon Group Holdings Ltd

Blue Moon Metals Inc

BLUE MOON METALS INC by BLUE MOON METALS INC.

BLUE NOTE MINING INC NEW by Blue Note Mining Inc.

Blue Note Mining Inc

Blue Ocean Acquisition Corp

Blue Ocean Acquisition Corp - Class A Ordinary Shares

Blue Owl Capital Corporation Common Stock

Blue Owl Capital Corp

Blue Owl Capital Corporation III Common Stock

Blue Owl Capital Corp III

Blue Owl Capital Inc. Class A Common Stock

Blue Owl Capital Inc

Blue Ribbon Income Fund

Blue Ridge Bankshares Inc

BLUE RIDGE REAL ESTATE CO by Blue Ridge Real Estate Co.

Blue Ridge Real Estate Co

BLUE RIVER RES LTD ORD by Blue River Resources, Ltd.

Blue River Resources Ltd

BLUE SKY URANIUM CORP by Blue Sky Uranium Corp.

Blue Sky Uranium Corp

Blue Sphere Corp

Blue Star Foods Corp

BLUE STAR GLOBAL INC by Blue Star Global, Inc.

Blue Star Global Inc

BLUE STAR GOLD CORP by Blue Star Gold Corp.

Blue Star Gold Corp

BLUE STAR HELIUM LTD by Blue Star Helium Ltd.

Blue Star Helium Ltd

BLUE STAR OPPTYS CORP by Blue Star Opportunities Corp.

Blue Star Opportunities Corp

BLUE WATER GLOBAL GRP INC by Blue Water Global Group, Inc.

Blue Water Global Group Inc

BLUE WATER PETROLEUM CP by Blue Water Petroleum Corp.

Blue Water Petroleum Corp

BLUE WATER VENTURES INC by Blue Water Ventures International, Inc.

Blue Water Ventures International Inc

Blue World Acquisition Corp Warrants (10/01/2029)

Blue World Acquisition Corp

Blue World Acquisition Corp Units (1 Ord Class A & 1/2 War & 1 Right)

BLUEFIRE EQUIPMENT CORP by BlueFire Equipment Corp.

BlueFire Equipment Corp

BLUEHARBOR BANK (NC) by BlueHarbor Bank (Mooresville NC)

BlueHarbor Bank

BlueLinx Holdings Inc

BlueRiver Acquisition Corp Units (1 Ord Share Class A & 1/3 War)

BlueRiver Acquisition Corp

BLUERIVER ACQ CORP A by BlueRiver Acquisition Corp.

BlueRiver Acquisition Corp Warrants (04/01/2026)

BlueRush Inc

BLUESCOPE STEEL LTD by Bluescope Steel, Ltd.

BlueScope Steel Ltd

BLUESCOPE STL UNS/ADR NEW by Bluescope Steel, Ltd.

BLUEBERRIES MEDICAL CO by Blueberries Medical Co.

Blueberries Medical Corp

Bluegreen Vacations Holding Corp Class B

Bluegreen Vacations Holdings Corp Com Cl A

Bluejay Diagnostics Inc

Blueone Card Inc

Blueprint Chesapeake Multi-Asset Trend ETF

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

BLUEPRINT TECHS INC by Blueprint Technologies, Inc.

Blueprint Technologies Inc

Bluerock Homes Trust, Inc. Class A Common Stock

Bluerock Homes Trust Inc

BLUESKY DIGITAL ASSET CRP by Bluesky Digital Assets Corp.

Bluesky Digital Assets Corp

BLUESTEM GROUP INC by Bluestem Group Inc.

Bluestem Group Inc

BLUESTONE RESOURCES ORD by Bluestone Resources, Inc.

Bluestone Resources Inc

On Thursday, Bluebird Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41967541/bluebird-bio-reports-third-quarter-2024-results-and-highlights-operational-progress-and-2024-guida" rel="noreferrer noopener">consensus loss of 36 cents</a>.
The gene therapy company reported sales of $10.6 million, down from $12.39 million, missing the consensus of $18.1 million.
The company&#8217;s cash, cash equivalents, and restricted cash balance were approximately&nbsp;$118.7 million, which is expected to provide a cash runway into the first quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41290857/worries-mount-over-cancer-risks-in-bluebird-bios-gene-therapy" rel="noreferrer noopener">Worries Mount Over Cancer Risks in Bluebird Bio&#8217;s Gene Therapy</a>
The company anticipates quarterly cash flow break-even in the second half of 2025, assuming it scales to approximately 40 drug product deliveries per quarter and obtains additional cash resources to extend its runway.
JP Morgan downgraded Bluebird after the third-quarter results. The analyst notes a reduced cash runway to &#8220;into 1Q25&#8221; from &#8220;into 2Q25.&#8221;
JP Morgan highlights that Bluebird did achieve the milestone of its first Lyfgenia infusion during the quarter (and revenue recognition) and continues to increase the pace of patient starts (cell collections) across its portfolio but is doing so against a backdrop of continued negative gross margins.
<ul>
<li>57 patient starts completed to date in 2024 (35 Zynteglo, 17 Lyfgenia, 5 Skysona).</li>
<li>Seventeen additional starts are scheduled through the remainder of 2024.</li>
</ul>
&#8220;Altogether presenting few avenues to emerge from remaining a going concern,&#8221; the analyst says. JP Morgan has downgraded from <a href="https://www.benzinga.com/quote/BLUE/analyst-ratings" target="_blank" rel="noreferrer noopener">Neutral to Underweight</a>.
The analyst writes that the proxy vote did not gather enough support to approve a reverse stock split and increase the number of shares available for issuance. This outcome effectively eliminates equity financing as an option for raising capital.
In September, Bluebird bio implemented a restructuring to optimize its cost structure and enable quarterly cash flow break-even in the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41008825/gene-therapy-focused-bluebird-bio-restructures-cuts-is-workforce-by-25-seeks-to-breakeven-next-ye" rel="noreferrer noopener">second half of 2025</a>.
Price Action: BLUE stock is down 11.2% at $0.32 at last check Friday.
Photo by Ground Picture on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012924/mullen-drives-into-government-sector-with-electric-bollinger-b4-trucks" target="_blank" rel="noreferrer noopener">Mullen Drives Into Government Sector With Electric Bollinger B4 Trucks</a></li>
</ul>

Analyst Color

Biotech

Earnings

Equities

News

Downgrades

Analyst Ratings

Movers

Trading Ideas

General

BLUE

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

RBC Capital analyst Luca Issi reiterates bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Sector Perform and maintains $4 price target.

Price Target

Reiteration

RBC Capital Reiterates Sector Perform on bluebird bio, Maintains $4 Price Target

B of A Securities analyst Jason Gerberry downgrades bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) from Buy to Neutral and lowers the price target from $3 to $0.5.

B of A Securities Downgrades bluebird bio to Neutral, Lowers Price Target to $0.5

Barclays analyst Gena Wang maintains bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Overweight and lowers the price target from $4 to $2.

Barclays Maintains Overweight on bluebird bio, Lowers Price Target to $2

Guidance

bluebird bio Sees Q4 2024 Revenue At Least $25M Vs $27.85M Estimate

bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. The company reported quarterly sales of $10.60 million which missed the analyst consensus estimate of $18.05 million by 41.27 percent. This is a 14.46 percent decrease over sales of $12.39 million the same period last year.

Comments

bluebird bio

Actualités

Dernières nouvelles pour bluebird bio (NASDAQ:BLUE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL